Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.32 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14220461 | 0.82 | RARB (0.37) | IKBKETBK1SUV39H2 | |
| SCHEMBL8453606 | 0.79 | TBK1 (0.36) | IKBKETBK1SUV39H2 | |
| SCHEMBL14403246 | 0.78 | TBK1 (0.43) | IKBKETBK1SUV39H2 | |
| SCHEMBL19721917 | 0.76 | IKBKE (0.32) | IKBKETBK1SUV39H2 | |
| SCHEMBL22816649 | 0.76 | IKBKE (0.38) | IKBKETBK1SUV39H2 | |
| SCHEMBL17471333 | 0.76 | TBK1 (0.40) | IKBKETBK1SUV39H2 | |
| SCHEMBL10131970 | 0.75 | IKBKE (0.36) | IKBKETBK1SUV39H2 | |
| SCHEMBL745424 | 0.73 | TBK1 (0.39) | IKBKETBK1SUV39H2 | |
| SCHEMBL21171825 | 0.72 | IKBKE (0.38) | IKBKETBK1SUV39H2 | |
| SCHEMBL612793 | 0.72 | TBK1 (0.36) | IKBKETBK1SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787608-B2 | Liquid crystal display device including liquid crystal medium containing low molecular weight polar compound for homogeneously aligning liquid crystal medium | JNC CORPORATION (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20190292462-A1 | LIQUID CRYSTAL DISPLAY DEVICE INCLUDING LIQUID CRYSTAL MEDIUM CONTAINING LOW MOLECULAR WEIGHT POLAR COMPOUND FOR HOMOGENEOUSLY ALIGNING LIQUID CRYSTAL MEDIUM | JNC CORPORATION (JP) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787608-B2 | Liquid crystal display device including liquid crystal medium containing low molecular weight polar compound for homogeneously aligning liquid crystal medium | ACP1, MAPK1, PLD1 | IKBKE 4596/4885TBK1 3861/4885MGAT2 1175/4885 |
| US-20190292462-A1 | LIQUID CRYSTAL DISPLAY DEVICE INCLUDING LIQUID CRYSTAL MEDIUM CONTAINING LOW MOLECULAR WEIGHT POLAR COMPOUND FOR HOMOGENEOUSLY ALIGNING LIQUID CRYSTAL MEDIUM | ACP1, MAPK1, PLD1 | IKBKE 4596/4885TBK1 3861/4885MGAT2 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.